--News Direct--
Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with details of data from the Phase 2 CALLIPER and CALVID-1 trials of vidofludimus calcium the company will present at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 in West Palm Beach, Florida, from today.
Vitt highlighted the significant potential of the drug in treating multiple sclerosis (MS), particularly in relation to Epstein-Barr Virus (EBV) reactivation.
The CALLIPER study focuses on the effects of 45 milligrams of vidofludimus calcium in patients with progressive MS, emphasising the importance of progression independent of relapse activity. October's interim biomarker data, specifically neurofilament light chain (NFL), which is related to neuronal death, was mentioned as a key aspect of the first poster. This data aims to correlate NFL reduction with the likelihood of future disability outcomes in progressive MS patients.
The overlap between the CALLIPER study and the Phase 2 CALVID-1 trial, outlined in the second poster, explores the role of EBV reactivation in MS and fatigue symptoms. Vidofludimus calcium's potential to prevent EBV reactivation and reduce fatigue in MS patients is a significant finding, with implications for post-COVID syndrome as well.
The CALVID-1 study also examined Vidofludimus calcium's effects on fatigue in patients treated for SARS-CoV-2, revealing a positive impact.
Presenting at the ACTRIMS Forum 2024, an important scientific conference for MS research, underscores the relevance and potential impact of Immunic Inc's findings in the MS and broader medical communities.
Contact DetailsProactive North America
+1 604-688-8158
NA-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/immunic-to-reveal-promising-ms-treatment-data-in-two-poster-presentations-at-actrims-forum-2024-959290636
